好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sarcoidosis-Associated Small Fiber Neuropathy: Clinical Features and Response to Immunosuppression
Autoimmune Neurology
P6 - Poster Session 6 (11:45 AM-12:45 PM)
8-003

To describe a cohort of patients with sarcoidosis-associated small fiber neuropathy (S-SFN) and their response to immunosuppression.

Small fiber neuropathy (SFN) affects up to 40% of sarcoidosis patients, causing chronic pain and disability. Risk factors and responses to immunosuppression are not well understood.

Retrospective study of biopsy-proven S-SFN patients, excluding those with large fiber neuropathy. We compared clinical characteristics and treatment responses between two groups: those with sarcoidosis without other risks for SFN (group 1) and those with sarcoidosis and additional risk factors for SFN (group 2). 
: Thirty-seven patients were included; 23 (62%) were female. Presenting symptoms included pain (22, 60%), paresthesias (20, 54%), and numbness (20, 54%). Other symptoms were dysautonomia (18, 49%), fatigue (15, 41%), and brain fog (10, 27%). Additional contributors to SFN were identified in 24 patients (65%) (group 2); with diabetes (18, 49%), chronic kidney disease (6, 16%), and vitamin B12 deficiency (4, 13%) being the most frequent. The median follow-up was 26 months (IQR 12–47). Despite treatment with corticosteroids (97%) and standard sarcoidosis therapies, most patients experienced worsening symptoms (40% in group 1 vs. 53% in group 2, p=0.79). At follow-up, 33% had a mRS score ≥3, with worsening in group 1 being more common than in group 2 (40% vs 6%, p-value: 0.02). Symptom improvement was reported with adalimumab (5 of 10, 50%), IVIG (2 of 4, 50%), infliximab (4 of 10, 40%), and tocilizumab (3 of 4, 75%), with the highest response to TNF-alpha inhibitors in group 1 (50% vs. 42%).

S-SFN is associated with chronic symptoms, including pain, dysautonomia, fatigue, and brain fog, with many patients worsening over time. Immunotherapies show promise, particularly TNF alpha inhibitors, IVIG, and tocilizumab. Identifying contributing comorbidities and exploring novel treatment options is essential for improving outcomes.
Authors/Disclosures
María Paula Aguilera Peña, MD
PRESENTER 		María Paula Aguilera Peña, MD has nothing to disclose.
Barney J. Stern, MD, FAAN (Johns Hopkins Outpatient Center) Dr. Stern has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Foundation for Sarcoidosis Research. The institution of Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. Dr. Stern has received publishing royalties from a publication relating to health care.
Carlos A. Pardo-Villamizar, MD (Johns Hopkins U, Med Dept of Neurology) The institution of Dr. Pardo-Villamizar has received research support from National Institutes of Health. The institution of Dr. Pardo-Villamizar has received research support from Bart McLean Fund for Neuroimmunology Research .
Paula Barreras, MD (Cedars-Sinai Medical Center) Dr. Barreras has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Barreras has received research support from Foundation for Sarcoidosis Research. The institution of Dr. Barreras has received research support from 好色先生.